CAS |
154229-19-3 |
Chinese Name |
阿比特龙 |
English Name |
Abiraterone |
Synonyms |
CB-7598;SPA-110;坦度酮罗;Abiraterone; |
Molecular Formula |
C24H31NO |
Molecular Weight |
349.51 |
Solubility |
Soluble in DMSO/Ethanol ≥2mg/mL |
Purity |
HPLC≥98% |
Appearance |
White to off-white Solid |
Storage |
Powder:2-8℃,2 years;Insolvent(Mother Liquid):-20℃,6 months;-80℃,1 year |
EC |
EINECS 810-941-6 |
MDL |
MFCD00924100 |
SMILES |
C[C@@]12C(C3=CN=CC=C3)=CC[C@]1([C@@]4(CC=C5[C@@](C)([C@]4(CC2)[H])CC[C@@H](C5)O)[H])[H] |
Target Point |
Cytochrome P450 |
Passage |
Metabolic Enzyme&Protease |
Background |
Abiraterone is a potent and selective irreversible CYP17 inhibitor. |
Biological Activity |
Abiraterone 是一种有效的选择性的不可逆 CYP17 抑制剂, IC50 为 2 到 4 nM[1]。 |
IC50 |
IC50: 2 to 4nM (CYP17) [1] |
In Vitro |
用阿齐拉酮≥5μM剂量显着抑制AR阳性前列腺癌细胞系LNCaP和VCaP的增殖[2]。对于17,20-裂解酶和17α-羟化酶,阿比特龙显示15nM和2.5nM的IC 50值(CYP17是具有17α-羟化酶和17,20-裂解酶活性的双功能酶)。阿比特龙抑制人17,20-裂解酶和17α-羟化酶,IC50分别为27和30 nM [3]。阿比特龙抑制重组人3βHSD1和3βHSD2活性,竞争性Ki值为2.1和8.8μM。 10μM阿比特龙足以完全阻断两种细胞系中5α-二酮和DHT的合成。用强烈生长的亚组显着抑制CR1进展,有效地在治疗4周内对肿瘤生长进行了上限(P <0.00001)。 LNCaP中阿比特龙抑制[3H] - 脱氢表雄酮(DHEA)消耗和Δ4-雄烯二酮(AD)积累,IC50 <1μM[4]。 |
In Vivo |
先前显示0.5mmol / kg / d阿比特龙治疗剂量产生约0.5至1μM的血清浓度。对照组的异种移植肿瘤生长变化很大,一些肿瘤生长缓慢,只有一部分肿瘤表现出强劲的生长[4]。静脉内给药(5mg / kg)后,清除率(Cl)和分布容积(Vd)分别为31.2mL / min / kg和1.97L / kg。发现AUC0-∞(从零时间到无限时间点的血浆浓度 - 时间曲线下面积)为2675ng * h / mL。终端半衰期(t1 / 2)为0.73小时。由于高清除率,阿比特龙(ART)仅在静脉内给药后2小时才能量化[5]。 |
Cell Experiment |
将LNCaP和VCaP细胞接种在96孔板中,并在补充CSS的无酚红或FBS补充的培养基中生长7天。在接种后24和96小时,用阿比特龙(5μM和10μM)处理细胞,并通过添加CellTiter Glo并测量发光在第7天测定细胞活力[2]。 |
Animal Experiment |
小鼠[4]通过手术切除睾丸切除6-8周龄的雄性NOD / SCID小鼠并植入5mg 90天持续释放DHEA小丸以模拟具有人肾上腺生理学的CRPC。两天后,用Matrigel皮下注射7×106个LAPC4细胞。肿瘤尺寸每周测量2至3次,体积计算为长×宽×高×0.52。一旦肿瘤达到300mm 3,将小鼠随机分配到载体或阿比特龙治疗组。阿比特龙组小鼠用5 mL / kg腹腔注射0.5 mmol / kg / d(0.1 mL 5%苄醇和95%红花油溶液)和对照小鼠仅用载体治疗,每日一次,每周5天以上持续4周(每次治疗n = 8只小鼠)。基于混合效应模型,通过ANOVA评估阿比特龙和媒介物治疗组之间的统计学显着性。大鼠[5]使用雄性Sprague-Dawley大鼠(n = 8,240-260g)。在静脉注射5mg / kg剂量的ART后,将血液样品(450μL)加入含有Na2-EDTA溶液作为抗凝剂的聚丙烯管中,并在给药前给药,0.12,0.25,0.5,1,2,4,6,8 24小时(在血液采集期间采用稀疏采样方案,并且在每个时间点从四只动物采集血液)。通过使用Biofuge在1760g离心血液5分钟来收获血浆,并在-80±10℃下冷冻储存直至分析。 |
Data Literature Source |
[1]. Attard G, et al. Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J Clin Oncol. 2008 Oct 1; 26 (28) :4563-71. [2]. Richards J, et al. Interactions of abiraterone, eplerenone, and prednisolone with wild-type and mutant androgen receptor: a rationale for increasing abiraterone exposure or combining with MDV3100. Cancer Res. 2012 May 1; 72 (9) :2176-82. [3]. Stein MN, et al. Androgen synthesis inhibitors in the treatment of castration-resistant prostate cancer. Asian J Androl. 2014 May-Jun; 16 (3) :387-400. [4]. Li R, et al. Abiraterone inhibits 3β-hydroxysteroid dehydrogenase: a rationale for increasing drug exposure in castration-resistant prostate cancer. Clin Cancer Res. 2012 Jul 1; 18 (13) :3571-9. [5]. Kumar SV, et al. Validated RP-HPLC/UV method for the quantitation of abiraterone in rat plasma and its application to a pharmacokinetic study in rats. Biomed Chromatogr. 2013 Feb; 27 (2) :203-7. |
Unit |
Bottle |
Specification |
50mg 100mg |